$58.77
0.68%
Nasdaq, Apr 21, 08:43 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$59.17
-12.38 17.30% 1M
-10.30 14.83% 6M
-6.56 9.98% YTD
-31.30 34.60% 1Y
-22.01 27.11% 3Y
-29.95 33.61% 5Y
-61.74 51.06% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.35 0.60%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Market capitalization $11.35b
Enterprise Value $10.86b
P/E (TTM) P/E ratio 26.90
EV/FCF (TTM) EV/FCF 22.28
EV/Sales (TTM) EV/Sales 3.82
P/S ratio (TTM) P/S ratio 4.00
P/B ratio (TTM) P/B ratio 1.99
Revenue growth (TTM) Revenue growth 17.35%
Revenue (TTM) Revenue $2.84b
EBIT (operating result TTM) EBIT $475.21m
Free Cash Flow (TTM) Free Cash Flow $487.42m
Cash position $1.14b
EPS (TTM) EPS $2.20
P/E forward 18.68
P/S forward 3.61
EV/Sales forward 3.46
Short interest 3.13%
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

25x Buy
81%
6x Hold
19%

Analyst Opinions

31 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
81%
Hold
19%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,839 2,839
17% 17%
100%
- Direct Costs 623 623
8% 8%
22%
2,216 2,216
20% 20%
78%
- Selling and Administrative Expenses 897 897
12% 12%
32%
- Research and Development Expense 747 747
0% 0%
26%
572 572
92% 92%
20%
- Depreciation and Amortization 96 96
8% 8%
3%
EBIT (Operating Income) EBIT 475 475
145% 145%
17%
Net Profit 427 427
155% 155%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Neutral
PRNewsWire
4 days ago
SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m.
Negative
The Motley Fool
11 days ago
The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9.
Positive
Seeking Alpha
18 days ago
BioMarin Pharmaceutical Inc.'s primary endpoint was met in the phase 3 Pegasus study, which used Palynziq for the treatment of adolescent patients ages 12 - 17 with phenylketonuria. The company is set to file regulatory applications to expand the label of Palynziq for phenylketonuria patients in both the U.S. and European territories in 2nd half of 2025. The global phenylketonuria market size i...
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today